Opinion: How artificial intelligence can bolster Europe’s competitive edge in biopharma
In a year marked by European Parliament elections and setting of the European Union’s priorities for the next five years, it’s time for the EU to make innovation in health and biopharmaceuticals a strategic priority for the region’s resilience and security.
Europe is currently facing a competitiveness crisis. EU productivity has declined 1.2% in the fourth quarter of 2023 compared to the previous year, while U.S. productivity rose 2.6%. As France’s President Emmanuel Macron and Germany’s Chancellor Olaf Scholz wrote recently in the Financial Times, “Europe is experiencing its Zeitenwende” (change of era) and must rise to the challenge.
